1 / 18

Management of Obesity and Dyslipidemia

Management of Obesity and Dyslipidemia. Presented by : Faisal Hassan Hussain. Contents: *health education . *Diet therapy . *Exercise . *Drug . *Surgery. *Health Education : 1-Clarify the diagnosis (primary or secondry ) 2-clarify the degree of Obesity by Using BMI .

ilori
Download Presentation

Management of Obesity and Dyslipidemia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Management of Obesity and Dyslipidemia Presented by : Faisal Hassan Hussain

  2. Contents: *health education . *Diet therapy . *Exercise . *Drug . *Surgery.

  3. *Health Education : 1-Clarify the diagnosis (primary or secondry ) 2-clarify the degree of Obesity by Using BMI . 3- discuss with the patient the benefit of weight reduction . 4-discuss with the patient the objective of weight reduction a-to prevent further weight gain b-to reduce your weight by 2kg/month c-to prevent co morbidities 5-discuss with patient the preferred method for weight reduction a-diet therapy b-exercise c-drugs d-surgery

  4. *Diet therapy : Principle of diet therapy : 1-the total daily caloric contents of diet should be reduced 2-the total daily fat intake should be reduced <30% of total calories 3-Carbohydrates intake should represent >55% of total calories . 4- protein intake should be <15% of total calories 5-the daily cholesterol should be <300mg/day . 6-Daily fiber intake should be (20-30)g/day. 7-the initial calories intake should be reduced by 500kcal/day . 8- for the patient with BMI>35 ,the daily calories should be reduced by 500-1000 calories 9-the principle of weight reduction during the next 6 months should be about 10 kgs of the original weight (i.e.500g/week).

  5. *General advice helping obese patients to reduce their weight : 1-they should not fill the stomach . 2-they should take vegetable or fruits before main meal . 3- they should not take additional meals or fast meals . 4-they should not fill the plate with large amount of foods . 5-they should eat slowly graind food well 6-they should avoid diet rich in fat 7-they should drink a glass of water before meals 8- they should not eat while watching TV or reading 9-they should not eat salty meal .

  6. *Exercise therapy : Obese patients should always be prescribed exercise unless contraindicated .the type of exercise should be acceptable , suitable and desirable for patients .regular moderate exercise will tend to redce weight by 2.4%of the total body weight . e.g : 1- walking 2-3 miles for 40 min 2-playing basketball 40 min 3-swimming for 20 min

  7. *Drug therapy : Drug therapy is indicated if diet and exercise therapy fail to reduce BMI to less than 30 in obese patients with other risk factors (such hypertension ,diabetes , dyslipidemia,sleep apnea , and coronary artery disease ) BMI less than 27 in those patients such risk factors. There are 2 drugs approved by FDA for weight reduction loss . These medication can reduce weight by 6-10 % of the original body weight Sibutramine : MOA: norepinephrine ,dopamine , serotonine inhibitors Dose :5,10,15 mg/oral /daily Side effects :tachycardia , HTN. Orlistat : MOA: pancreatic lipase inhibitor (decrease fat absorption) Dose: 120mg 3 times before meal Side effects : decrease absorption of fat soluble vitamins (ADEK) , soft stool , and flatus . Note : if patient taking either medication has not lost at least 2 kgs on therapy for 4 weeks , the medication should be discontinued .

  8. *Surgery: Indication : Morbid obesity (BMI >40) if the medical therapy fails in reduction weight . Obesity (BMI>35) with cardiovascular risk factor . If the obese patient suffer from complication of obesity . Referral : If the behavioral and drug therapy fail to reduce weight gain If there is cardiovascular risk factor .

  9. Gastric bypass :

  10. Gastric sleeve:

  11. Management of Dyslipidemia

  12. Contents: *Diet therapy . *Exercise . *Drug .

  13. *Exercise therapy: The exercise should be performed four times ,30 min at least a week unless there is contraindication . walking and swimming are the optional type of exercise . Exercise will tend to decrease BP , blood sugar , weight ,LDL,TG, and will increase HDL .

  14. *Diet therapy: 1-The objective of diet therapy to reduce the LDL to less than 160 mg/dl for those without risk factor . 2-And to reduce LDL for less than 130mg/dl for those having two or more of risk factor . 3- and to reduce LDL for less than 100mg/dl for those having coronary artery disease Diet therapy will reduce LDL and TG within 6-8 weeks and should be continued for 6 moths before giving drug therapy unless there are good indication for initiation of drugs. Diet therapy will reduce LDL by 10-20%.

  15. *Drug therapy : It is indicated in the following : 1-if the lipid remain elevated after six months of diet therapy (did not decrease to the target) 2- If the initial LDL>190mg/dl. 3-If the TG>1000mg/dl Choices of drug depend upon the type of the elevated lipid For high LDLCstatinsis most effective drugs while high TG are preferred to be treated by Gemifibrozil or Nicotinic acid .

  16. Statins : MOA: HMG CO A reductase inhibitor . Side effects : muscle pain , high level of liver enzyme . Safety monitoring : creatinine , Kinase , liver enzyme . Gemifibrozil: MOA: Agonists of nuclear receptor PPARα (peroxisomeproliferator-activated receptor α) expressed in several types of cells such as hepatocytes, skeletal muscle fibres and macrophages . Side effects : GIT dysfunction and myosities . Safety monitoring: liver function test and coagulation profile Nicotinic acid : MOA : niacin inhibits lipase activity in the adipocytes. Side effect : flushing .hyperglycemia and hyperuricemia Safety monitoring : liver function test , uric acid , blood sugar .

  17. Thank you

More Related